RANGE AT RHEUMATOID ARTHRITIS AGAINST THERAPY THE RITUKSIMABY

Abstract

The main aim of our research was to study the dynamics of indexes of lipid profile from patients with rheumatoid arthritis during 52 weeks. We have found that the therapy with rituximab in combination with me- totrexate brings the reduction of clinic and immunological activities, improvement of functional activism in pa- tients and reduction of atherogenic factor.

Keywords

• ревматоидный артрит
• ритуксимаб
• липидный спектр
• rheumatoid arthritis
• rituximab
• blood lipid spectrum